Q-omics provides the consensus-scored TBC1D5 profile across patient tissues and cancer cell-line models. TBC1D5 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TBC1D5 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, TBC1D5 RNA expression shows 21,072 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LIHC, and THYM as cancer lineages where TBC1D5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D5 survival associations across molecular data types. TBC1D5 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D5 RNA expression–survival associations across cancer types. High TBC1D5 expression shows unfavorable associations in KICH, but favorable associations in KIRC, READ, LGG, COAD and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TBC1D5 RNA expression.
This table summarizes TBC1D5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TBC1D5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D5 shows lower tumor expression in THCA, KIRC, BRCA, KICH and LUSC and higher tumor expression in LIHC. The LIHC box plot shows higher TBC1D5 RNA expression in tumor versus normal tissue (log2 FC = +0.950, t-test p < 0.001).
This table shows molecular features associated with TBC1D5 in patient tissues and cancer cell lines. In patient samples, TBC1D5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
